JZP541
Phase 2Withdrawn 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Irritability Associated With Autism Spectrum Disorder
Conditions
Irritability Associated With Autism Spectrum Disorder, Autism Spectrum Disorder, ASD
Trial Timeline
Jun 30, 2023 → Nov 9, 2023
NCT ID
NCT05733390About JZP541
JZP541 is a phase 2 stage product being developed by Jazz Pharmaceuticals for Irritability Associated With Autism Spectrum Disorder. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05733390. Target conditions include Irritability Associated With Autism Spectrum Disorder, Autism Spectrum Disorder, ASD.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05733390 | Phase 2 | Withdrawn |
Competing Products
7 competing products in Irritability Associated With Autism Spectrum Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KarXT + KarX-EC + KarXT + KarX-EC Matching Placebo | Bristol Myers Squibb | Phase 3 | 76 |
| KarXT + KarX-EC + KarXT + KarX-EC Matching Placebo | Bristol Myers Squibb | Phase 3 | 76 |
| Aripiprazole + Placebo | Bristol Myers Squibb | Approved | 84 |
| Brexpiprazole + Placebo | Lundbeck | Phase 3 | 74 |
| Brexpiprazole | Lundbeck | Phase 3 | 74 |
| Pimavanserin | Acadia Pharmaceuticals | Phase 2/3 | 60 |
| Pimavanserin + Placebo | Acadia Pharmaceuticals | Phase 2/3 | 60 |